SCHEMBL859948

SCHEMBL859948

N#CCCCCSC(=N)N

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 5/20 0.52
CYP2C19 P33261 3/20 0.52
NOS1 P29475 7/20 0.50
HRH4 Q9H3N8 5/20 0.50
NOS3 P29474 4/20 0.50
NOS2 P35228 4/20 0.50
HSD17B10 Q99714 1/20 0.48
ALDH1A1 P00352 2/20 0.47
TDP1 Q9NUW8 3/20 0.45
HRH2 P25021 1/20 0.45
MAPT P10636 2/20 0.44
TSHR P16473 2/20 0.44
CYP3A4 P08684 2/20 0.43
LMNA P02545 1/20 0.43
APEX1 P27695 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HRH3 Q9Y5N1 1/20 0.39
CYP2D6 P10635 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL860625 0.98 CYP1A2 (0.50) CYP1A2CYP2C19NOS1HRH4NOS3
Hydrochloric Acid SCHEMBL850423 0.98 CYP1A2 (0.50) CYP1A2CYP2C19NOS1HRH4NOS3
Hydrochloric Acid SCHEMBL860518 0.96 ALDH1A1 (0.48) CYP1A2CYP2C19NOS1HRH4NOS3
4-Isothioureidobutyronitrile SCHEMBL851495 0.93
4-Isothioureidobutyronitrile SCHEMBL851612 0.91 CYP1A2 (0.52) CYP1A2CYP2C19NOS1HRH4NOS3
4-Isothioureidobutyronitrile SCHEMBL20607675 0.89 CYP1A2 (0.50) CYP1A2CYP2C19NOS1HRH4NOS3
SCHEMBL851824 0.84
Hydrochloric Acid SCHEMBL849818 0.82
Bromide SCHEMBL8605247 0.82
SCHEMBL9193111 0.78 CYP1A2 (0.71) CYP1A2CYP2C19NOS1HRH4NOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2432464-B1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS INNOVATION PHARMACEUTICALS INC (US) 2019-01-09 EP claimed
US-9610275-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2017-04-04 US claimed
CN-102438612-B Nitrile derivatives, their pharmaceutical use and compositions CELLCEUTIX CORP. (US) 2016-02-03 CN claimed
US-20130245062-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2013-09-19 US claimed
US-8338454-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2012-12-25 US claimed
US-20120189537-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION 2012-07-26 US claimed
EP-2432464-A2 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS Cellceutix Corporation (US) 2012-03-28 EP claimed
WO-2010135170-A2 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 WO claimed
US-20100298374-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 US claimed
EP-2432464-B1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS INNOVATION PHARMACEUTICALS INC (US) 2019-01-09 EP disclosed
US-9610275-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2017-04-04 US disclosed
US-9610275-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2017-04-04 US disclosed
US-9610275-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2017-04-04 US disclosed
US-9340491-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2016-05-17 US disclosed
US-20120189537-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION 2012-07-26 US disclosed
EP-2432464-A2 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS Cellceutix Corporation (US) 2012-03-28 EP disclosed
WO-2010135170-A2 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 WO disclosed
US-20100298374-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 US disclosed
US-20100298374-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 US disclosed
US-20100298374-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245062-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS NOS1, NOS2, NOS3 CYP1A2 325/4885CYP2C19 296/4885NOS1 1/4885
US-20120189537-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS NOS1, NOS2, NOS3 CYP1A2 325/4885CYP2C19 296/4885NOS1 1/4885
US-20100298374-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS NOS1, NOS2, NOS3 CYP1A2 325/4885CYP2C19 296/4885NOS1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.